The mucopolysaccharidosis treatment market size is expected to grow from USD 3.01 billion in 2025 to USD 3.28 billion in 2026 and is forecast to reach USD 4.98 billion by 2031 at 8.72% CAGR over 2026-2031. This report is segmented by Treatment Modality (Enzyme Replacement Therapy, Stem-Cell Therapy/HSCT, and More), MPS Type (MPS I, MPS II, MPS III, MPS IV, MPS VI, MPS VII, Ultrarare Types), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
The mucopolysaccharidosis gene therapy market is projected to accelerate once manufacturing constraints ease, yet payers are scrutinizing the post-treatment monitoring, which adds USD 80,000-120,000 per patient over 15 years. ERT incumbents face mounting price pressure; BioMarin’s laronidase revenue slipped 6% in 2024 despite moderate patient growth. Orchard’s OTL-203 produced 88% event-free survival at three-year follow-up, securing EMA PRIME status in January 2025.
Japan’s approval of pabinafusp alfa drove first-year sales of JPY 4.2 billion (USD 28 million). China’s CANbridge filed MPS I and II therapies in late 2024, targeting an estimated 1,200 diagnosed patients. South Korea reimbursed elosulfase alfa in January 2025, reflecting growing political will to fund ultra-rare therapies. Latin America and MEA combined represented 11% of 2025 revenue, constrained by diagnostic delays and fragmented payer systems; however, Brazil’s inclusion of laronidase and idursulfase into its high-cost drug program in April 2024 expanded access to roughly 340 patients.
Global Mucopolysaccharidosis Treatment Market Trends and Insights
Expanding Newborn Screening Mandates
Mandatory inclusion of MPS I and MPS II in state panels has shortened diagnostic journeys from a median of 4.2 years to under six months, with 47 U.S. jurisdictions now screening for MPS I and 18 for MPS II. Early identification allows ERT before irreversible organ damage, lifting five-year survival from 68% to 91% in screened cohorts. Payers now see pre-symptomatic therapy lowering lifetime hospitalization costs by USD 1.2 million per patient, a dynamic that is motivating policymakers in the European Union to consider adding additional subtypes to national screening programs.Regulatory Momentum for BBB-Penetrant ERT Approvals
Japan’s March 2024 green light for pabinafusp alfa ushered in the first enzyme engineered to traverse the blood-brain barrier. Seventy-two percent of patients showed stabilization or gains on Vineland Adaptive Behavior Scales after 52 weeks, a benchmark unmet by previous idursulfase regimens. ArmaGen’s fusion construct for MPS I entered late-stage U.S. trials in November 2024, with interim cerebrospinal fluid enzyme data expected mid-2026. These advances expand the addressable market because neuronopathic phenotypes represent 42% of cases but historically accounted for only 18% of ERT spending.Reimbursement Caps for Ultra-High-Cost Orphan Biologics
England’s cost watchdog declined ERT funding with ICERs above GBP 1 million per QALY, and Germany cut galsulfase prices 22% after downgrading its benefit rating. Gene-therapy list prices of USD 2.5-4 million are triggering five-year outcome-based contracts, extending market-access timelines by up to 18 months.Other drivers and restraints analyzed in the detailed report include:
- Surging Venture Investment in CNS-Targeted Gene Therapies
- Rapid Adoption of Home-Infusion Models in High-Income Markets
- Manufacturing Yield Bottlenecks for High-Dose AAV Vectors
Segment Analysis
Enzyme replacement therapy held 73.81% of the mucopolysaccharidosis treatment market share in 2025, anchored by decades of longitudinal safety data and established reimbursement pathways. Gene therapy, however, is forecast to surge at a 9.26% CAGR through 2031, signaling a pivot toward one-time curative vectors that circumvent lifelong infusions. REGENXBIO’s RGX-121 achieved its primary endpoint in 19 of 21 evaluable patients, making a late-2026 FDA filing plausible. Stem-cell transplants remain a niche, with roughly 80 procedures annually worldwide, although Sangamo’s autologous zinc-finger approach could triple the addressable cohort.The mucopolysaccharidosis gene therapy market is projected to accelerate once manufacturing constraints ease, yet payers are scrutinizing the post-treatment monitoring, which adds USD 80,000-120,000 per patient over 15 years. ERT incumbents face mounting price pressure; BioMarin’s laronidase revenue slipped 6% in 2024 despite moderate patient growth. Orchard’s OTL-203 produced 88% event-free survival at three-year follow-up, securing EMA PRIME status in January 2025.
Complete Report Scope:
- By Treatment Modality
- Enzyme Replacement Therapy (ERT)
- Stem-Cell Therapy / HSCT
- Gene Therapy
- Other Treatment Modality (Small-Molecule Modulators, Supportive & Adjunctive Therapies, etc.)
- By MPS Type
- MPS I (Hurler - Scheie)
- MPS II (Hunter)
- MPS III (Sanfilippo A-D)
- MPS IV (Morquio A/B)
- MPS VI (Maroteaux-Lamy)
- MPS VII (Sly)
- Ultrarare Types (e.g., MPS IX)
- By End User
- Hospitals
- Specialty Clinics
- Home-Infusion Settings
- Research & Academic Centers
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America delivered 41.43% of 2025 revenue, underpinned by widespread newborn screening, high diagnosis rates, and favorable reimbursement. Europe followed at 32%, aided by national rare-disease plans that centralize procurement and negotiate volume rebates. The mucopolysaccharidosis treatment market in Asia-Pacific is forecast to grow the fastest, at a 13.42% CAGR through 2031, as Japan, China, and South Korea expand coverage.Japan’s approval of pabinafusp alfa drove first-year sales of JPY 4.2 billion (USD 28 million). China’s CANbridge filed MPS I and II therapies in late 2024, targeting an estimated 1,200 diagnosed patients. South Korea reimbursed elosulfase alfa in January 2025, reflecting growing political will to fund ultra-rare therapies. Latin America and MEA combined represented 11% of 2025 revenue, constrained by diagnostic delays and fragmented payer systems; however, Brazil’s inclusion of laronidase and idursulfase into its high-cost drug program in April 2024 expanded access to roughly 340 patients.
List of Companies Covered in this Report:
- Abeona Therapeutics
- Allievex Corporation
- ArmaGen
- Avrobio
- BioMarin Pharmaceutical
- CANbridge Life Sciences
- Denali Therapeutics
- Esteve Pharma
- GC Biopharma
- Immusoft Corporation
- Inventiva S.A.
- JCR Pharmaceuticals
- Lysogene
- Orchard Therapeutics
- Paradigm Biopharmaceuticals
- REGENXBIO
- Sangamo Therapeutics
- Sanofi
- Takeda Pharmaceuticals
- Ultragenyx Pharmaceutical
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abeona Therapeutics
- Allievex Corporation
- ArmaGen
- Avrobio
- BioMarin Pharmaceutical
- CANbridge Life Sciences
- Denali Therapeutics
- Esteve Pharma
- GC Pharma
- Immusoft Corporation
- Inventiva S.A.
- JCR Pharmaceuticals
- Lysogene
- Orchard Therapeutics
- Paradigm Biopharmaceuticals
- REGENXBIO
- Sangamo Therapeutics
- Sanofi SA
- Takeda Pharmaceutical
- Ultragenyx Pharmaceutical
